← Eichor
Condition: Meningitis Bacterial Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Meningitis Bacterial

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Olorofim in Early Coccidioidal Meningitis
Phase 2 · 1 location(s) · Fariba Donovan · NCT07385638Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
Phase N/A · 1 location(s) · Institut Pasteur du Cambodge · NCT07358910Adjunctive Doxycycline for Central Nervous System Tuberculosis
Phase 2 · 6 location(s) · National University Hospital, Singapore · NCT06446245Diagnostic of D-lactate in Cerebrospinal Fluid Level in Patients With Suspected Ventriculostomy-related Meningitis
NA · 1 location(s) · University Hospital, Toulouse · NCT06482463Fosfomycin I.v. for Treatment of Severely Infected Patients
Phase N/A · 50 location(s) · Infectopharm Arzneimittel GmbH · NCT02979951Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia
Phase N/A · 1 location(s) · National Institute of Allergy and Infectious Diseases (NIAID · NCT00867269Prospective Clinical Registry of Acute Treatment and Long-term Assessment of Children Meningitis
Phase N/A · 1 location(s) · Hospital Israelita Albert Einstein · NCT07062445National Bacterial Meningitis Study in Children and Newborns
Phase N/A · 1 location(s) · Association Clinique Thérapeutique Infantile du val de Marne · NCT04664569Febrile Infants Swedish Study
Phase N/A · 11 location(s) · Region Skane · NCT07134751Single Dose Liposomal Amphotericin for Asymptomatic Cryptococcal Antigenemia
Phase 2/Phase 3 · 1 location(s) · Makerere University · NCT03945448Intensified Tuberculosis Treatment to Reduce the Mortality of Patients With Tuberculous Meningitis
Phase 3 · 13 location(s) · ANRS, Emerging Infectious Diseases · NCT04145258Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Phase N/A · 2 location(s) · Sanford Health · NCT01793168Investigating Gender and Sex Differences in Immune Responses Through Vaccination of Transgender and Cisgender Persons
Phase 4 · 1 location(s) · University Ghent · NCT06832514Lebanese Interhospital Pneumococcal Surveillance Program
Phase N/A · 1 location(s) · American University of Beirut Medical Center · NCT00901602Platform Trial For Cryptococcal Meningitis (PLATFORM-CM)
Phase 2/Phase 3 · 2 location(s) · David Boulware · NCT06666322Fungal Infection Susceptibility
Phase N/A · 1 location(s) · National Institute of Allergy and Infectious Diseases (NIAID · NCT00001352Augmented Renal Clearance in Neurocritical Care
Phase N/A · 3 location(s) · University of Alberta · NCT07410624Acute Treatment and Long-term Assessment of Adult Infectious Meningitis
Phase N/A · 3 location(s) · Hospital Israelita Albert Einstein · NCT07027475Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135
Phase 1 · 1 location(s) · CanSino Biologics Inc. · NCT07203755Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard
Phase 2 · 18 location(s) · National Institute of Allergy and Infectious Diseases (NIAID · NCT05383742Tnf Inhibitors to Reduce Mortality in HIV-1 Infected PAtients With Tuberculosis meNIngitis
Phase 2 · 3 location(s) · ANRS, Emerging Infectious Diseases · NCT05590455Central Nervous System Infections in Denmark
Phase N/A · 8 location(s) · Aalborg University Hospital · NCT03418441
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.